Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Catalyst Biosciences, Inc. stock logo
CBIO
Catalyst Biosciences
$0.77
$0.19
$8.69
$291.29M1.05763,526 shs32,246 shs
Geron Co. stock logo
GERN
Geron
$1.45
-2.0%
$1.41
$1.17
$5.34
$923.53M0.7611.78 million shs11.88 million shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.26
-0.8%
$1.46
$1.19
$2.04
$999.25M1.423.91 million shs2.18 million shs
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
$7.89
-0.3%
$4.06
$0.83
$8.20
$546.26M0.49902,748 shs1.81 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Catalyst Biosciences, Inc. stock logo
CBIO
Catalyst Biosciences
0.00%0.00%0.00%0.00%0.00%
Geron Co. stock logo
GERN
Geron
0.00%+14.17%+2.11%-43.69%-60.38%
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.00%-5.26%-13.70%-25.00%-4.55%
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
0.00%+0.25%+181.79%+502.29%+310.94%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Catalyst Biosciences, Inc. stock logo
CBIO
Catalyst Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Geron Co. stock logo
GERN
Geron
4.1336 of 5 stars
4.41.00.01.33.63.30.6
OPKO Health, Inc. stock logo
OPK
OPKO Health
4.3931 of 5 stars
3.42.00.04.42.75.00.6
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
1.2911 of 5 stars
2.13.00.00.03.31.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Catalyst Biosciences, Inc. stock logo
CBIO
Catalyst Biosciences
0.00
N/AN/AN/A
Geron Co. stock logo
GERN
Geron
2.78
Moderate Buy$5.06249.14% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.75
Moderate Buy$2.75118.25% Upside
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
2.29
Hold$8.507.73% Upside

Current Analyst Ratings Breakdown

Latest CBIO, OPK, GERN, and RGLS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2025
Geron Co. stock logo
GERN
Geron
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeSector Outperform ➝ Sector Perform$4.00 ➝ $1.50
5/1/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
5/1/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$9.00
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$7.00
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$28.00 ➝ $11.00
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$8.00 ➝ $7.00
4/25/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral
4/7/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
3/27/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$3.00 ➝ $6.00
(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Catalyst Biosciences, Inc. stock logo
CBIO
Catalyst Biosciences
$790K0.00N/AN/A($0.78) per share0.00
Geron Co. stock logo
GERN
Geron
$116.29M7.94N/AN/A$0.46 per share3.15
OPKO Health, Inc. stock logo
OPK
OPKO Health
$689.41M1.45N/AN/A$1.80 per share0.70
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/AN/AN/AN/A$1.05 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Catalyst Biosciences, Inc. stock logo
CBIO
Catalyst Biosciences
-$8.24M-$1.38N/AN/AN/AN/A-364.68%-281.68%N/A
Geron Co. stock logo
GERN
Geron
-$184.13M-$0.21N/AN/AN/A-682.48%-67.53%-45.46%N/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$188.86M-$0.07N/AN/AN/A-18.65%-9.76%-6.46%8/6/2025 (Estimated)
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
-$30.04M-$0.73N/AN/AN/AN/A-53.07%-48.58%N/A

Latest CBIO, OPK, GERN, and RGLS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
-$0.29-$0.15+$0.14-$0.15N/AN/A
5/7/2025Q1 2025
Geron Co. stock logo
GERN
Geron
-$0.04-$0.03+$0.01-$0.03$49.88 million$39.60 million
4/30/2025Q1 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.10-$0.03-$0.10$163.13 million$149.90 million
3/20/2025Q4 2024
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
-$0.20-$0.20N/A-$0.20N/AN/A
2/27/2025Q4 2024
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.08$0.01+$0.09$0.01$155.42 million$183.60 million
2/26/2025Q4 2024
Geron Co. stock logo
GERN
Geron
-$0.04-$0.04N/A-$0.04$45.29 million$47.54 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Catalyst Biosciences, Inc. stock logo
CBIO
Catalyst Biosciences
N/AN/AN/AN/AN/A
Geron Co. stock logo
GERN
Geron
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Catalyst Biosciences, Inc. stock logo
CBIO
Catalyst Biosciences
N/A
2.88
2.88
Geron Co. stock logo
GERN
Geron
0.04
2.89
2.74
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.30
2.97
2.69
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/A
14.15
14.14

Institutional Ownership

CompanyInstitutional Ownership
Catalyst Biosciences, Inc. stock logo
CBIO
Catalyst Biosciences
5.98%
Geron Co. stock logo
GERN
Geron
73.71%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
92.38%

Insider Ownership

CompanyInsider Ownership
Catalyst Biosciences, Inc. stock logo
CBIO
Catalyst Biosciences
2.92%
Geron Co. stock logo
GERN
Geron
7.42%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
4.35%
CompanyEmployeesShares OutstandingFree FloatOptionable
Catalyst Biosciences, Inc. stock logo
CBIO
Catalyst Biosciences
737.98 million36.87 millionOptionable
Geron Co. stock logo
GERN
Geron
70636.92 million585.76 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
4,200793.05 million359.94 millionOptionable
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
3069.23 million62.65 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Catalyst Biosciences stock logo

Catalyst Biosciences NASDAQ:CBIO

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.

Geron stock logo

Geron NASDAQ:GERN

$1.45 -0.03 (-2.03%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$1.44 -0.01 (-0.62%)
As of 05/23/2025 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.26 -0.01 (-0.79%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$1.27 +0.01 (+0.79%)
As of 05/23/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Regulus Therapeutics stock logo

Regulus Therapeutics NASDAQ:RGLS

$7.89 -0.02 (-0.25%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$7.90 +0.00 (+0.06%)
As of 05/23/2025 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.